Theravance Biopharma, Inc. Payments of Debt Issuance Costs
Theravance Biopharma, Inc. (TBPH) reported Payments of Debt Issuance Costs of $5.33 million for the 12-month period ending 2020-12-31, per its 10-K filed 2022-02-28.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2022-02-28
- Theravance Biopharma, Inc. payments of debt issuance costs for the quarter ending 2020-12-31 was $0.00.
- Theravance Biopharma, Inc. payments of debt issuance costs for the quarter ending 2020-09-30 was $0.00.
- Theravance Biopharma, Inc. payments of debt issuance costs for the quarter ending 2020-06-30 was $261.00K.
- Theravance Biopharma, Inc. payments of debt issuance costs for the quarter ending 2020-03-31 was $5.07M.
- Theravance Biopharma, Inc. payments of debt issuance costs for fiscal 2020 was $5.33M.
| Period end | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 6 month | Payments of Debt Issuance Costs 9 month | Payments of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $0.00 derived: sum of 2 quarters · filed 2022-02-28 | $261.00K derived: sum of 3 quarters · filed 2022-02-28 | $5.33M 10-K · filed 2022-02-28 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $261.00K derived: sum of 2 quarters · filed 2021-11-08 | $5.33M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $261.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $5.33M 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $5.07M 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |